Form 10-Q Lucid Diagnostics Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
May 14, 2024 8:01 AM EDTCanaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)
The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Before the market open on... More
